Expert oncologists Dr. Jeffrey Zonder and Dr. Shaji Kumar discuss AL amyloidosis background, typical patient profiles, and disease staging and risk stratification.
The Evolving Treatment Landscape in Light Chain Amyloidosis with Cardiac Involvement
Dr. Kumar discusses best practices for accurately and prompt diagnosing AL amyloidosis as well as navigating differential diagnosis.
Dr. Zonder discusses the current treatment landscape in AL amyloidosis, highlighting recent advances.
Expert oncologist Dr. Kumar provides his assessment of unmet needs in AL Amyloidosis, particularly patients with cardiac involvement.
Drs. Kumar and Zonder discuss results from the Phase III Vital trial investigating birtamimab and key takeaways.
Dr. Zonder discusses the safety profile of birtamimab in the VITAL study and the clinical implications.
Dr. Kumar discusses strategies for managing adverse events in patients with AL amyloidosis.
Dr. Kumar and Dr. Zonder discuss the ongoing confirmatory Phase III AFFIRM-AL trial investigating the efficacy and safety of birtamimab and ongoing recruitment in the trial.
Expert oncologists discuss the progression treatment landscape in AL amyloidosis and agents of investigation.
Dr. Zonder and Dr. Kumar share their clinical pearls and perspectives on future directions in the treatment of AL amyloidosis.
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts NDA for Zanzalintinib Plus Atezolizumab in Pretreated mCRC
2
HPV Vaccination and Evolving Screening Strategies Continue to Shape Cervical Cancer Prevention Efforts
3
Retrospective, Real-World Analysis Shows Improved OS With Apalutamide Over Darolutamide in mCSPC
4
SC Daratumumab Plus VRd Expands Options in Newly Diagnosed, Transplant-Ineligible Myeloma
5